Publications

Supplementing your understanding of supplementary protection certificates

Supplementing your understanding of supplementary protection certificates

Thursday, February 01, 2018/Categories: Publications

11/10/2017 - Giorgio Long - IAM Weekly 
The Milan Court of First Instance recently addressed the validity of a supplementary protection certificate (SPC) held by Amgen based on a first marketing authorisation in Italy filed by Hoffmann La Roche (HLR), relating to the drug Kadcyla, which is used in the treatment of breast cancer.

Print
Download

Name:
Email:
Subject:
Message:
x

lara escort